Last reviewed · How we verify
IBI362
IBI362 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.
IBI362 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity. Used for Non-small cell lung cancer, Other solid tumors (in development).
At a glance
| Generic name | IBI362 |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Drug class | Bispecific antibody; PD-1/TGF-β inhibitor |
| Target | PD-1 and TGF-β |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
IBI362 functions as a PD-1/TGF-β bispecific antibody designed to block immune checkpoint inhibition via PD-1 while also neutralizing immunosuppressive TGF-β signaling. By targeting both pathways, the drug aims to overcome resistance to single-agent PD-1 inhibition and enhance T-cell activation and infiltration in the tumor microenvironment.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (in development)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Infusion-related reactions
Key clinical trials
- Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity (PHASE3)
- GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study) (PHASE3)
- A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity (PHASE3)
- A Study of IBI362 in Chinese Adolescents With Obesity or Overweight (PHASE3)
- Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity (PHASE1, PHASE2)
- A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) (PHASE2)
- A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects (PHASE2)
- This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBI362 CI brief — competitive landscape report
- IBI362 updates RSS · CI watch RSS
- Innovent Biologics (Suzhou) Co. Ltd. portfolio CI